The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vibegron (Obgemsa, Pierre Fabre) for treating overactive bladder (OAB) syndrome in adults. The ...

Medically reviewed by Jamin Brahmbhatt, MD Feeling like you need to pee right after using the bathroom is common and can be frustrating. These symptoms, known as urinary urgency and frequency, have ...

One in six adults have bladder control problems. It can disrupt sleep or cause accidents, lead to social isolation and depression and affects women more than men. Overactive bladder syndrome affects ...

Overactive bladder (OAB) is defined as urinary urgency, with or without urge incontinence, often with frequency and nocturia. Initial therapy of OAB often includes anticholinergics and behavioral ...

OAB is commonly treated with a class of medicines called anticholinergics or antimuscarinics. These medicines block chemicals in your body that help the bladder to squeeze. By blocking these chemicals ...

Dear D.J.: The initial treatment for OAB symptoms usually consists of lifestyle changes (i.e., quitting smoking, avoiding medications that worsen symptoms and excess fluid intake at night), pelvic ...

Bladder leaks can be disruptive—and they’re very common. Up to 30 percent of older adults experience incontinence. The problem is more prevalent in women, but the percentage of men with an overactive ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Overactive Bladder pipeline constitutes 15+ key companies continuously working towards developing 15+ ...

Holly Robinson Peete at the 17th Annual HollyRod Designcare Gala at The Lot on August 8, 2015, in West Hollywood, CA./Depositphotos *We spoke to actress, advocate, and philanthropist Holly Robinson ...

Please provide your email address to receive an email when new articles are posted on . Patients with overactive bladder had an odds ratio of 1.4 for osteoarthritis. Overactive bladder was not ...

TOKYO, Jul 23, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku ...